Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.53 |
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.50 |
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.50 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL811071 | 0.81 | PARP10 (0.46) | — | |
| SCHEMBL811055 | 0.81 | MRGPRX4 (0.39) | PDE10AALOX5AP | |
| SCHEMBL6583310 | 0.79 | CYSLTR1 (0.78) | PDE10AGPBAR1CYSLTR1CYSLTR2ALOX5AP | |
| SCHEMBL811334 | 0.78 | CYP1A2 (0.55) | — | |
| Hydrogen Sulfide SCHEMBL9818430 | 0.78 | CYSLTR1 (0.76) | PDE10AGPBAR1CYSLTR1CYSLTR2ALOX5AP | |
| SCHEMBL810520 | 0.77 | PARP10 (0.48) | — | |
| SCHEMBL8734106 | 0.76 | PDE10A (0.66) | PDE10AGPBAR1CYSLTR1CYSLTR2 | |
| SCHEMBL10512475 | 0.75 | PDE10A (0.77) | PDE10AGPBAR1CYSLTR1CYSLTR2 | |
| SCHEMBL810856 | 0.74 | MAOB (0.44) | ALOX5AP | |
| SCHEMBL810986 | 0.74 | PIM1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971611-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-10-10 | — | — | EP | disclosed |
| US-8236950-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-08-07 | — | — | US | disclosed |
| EP-2345652-A1 | Antiviral compounds | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-7915411-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-29 | — | — | US | disclosed |
| EP-2094276-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2009-09-02 | — | — | EP | disclosed |
| CN-101443334-A | Anti-viral compounds | ABBOTT LAB (US) | 2009-05-27 | — | — | CN | disclosed |
| WO-2008133753-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-1971611-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007081517-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | PDE10A 4218/4885GPBAR1 1851/4885CYSLTR1 4364/4885 |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | PDE10A 4218/4885GPBAR1 1851/4885CYSLTR1 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.